We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+1.9%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$3.17M
AUM Growth
+$561K
Cap. Flow
+$147M
Cap. Flow %
4,647.33%
Top 10 Hldgs %
63.1%
Holding
323
New
68
Increased
74
Reduced
74
Closed
84

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$37.9M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$24.5M
3
MRK icon
Merck
MRK
+$12.3M
4
GILD icon
Gilead Sciences
GILD
+$11.7M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$11.6M

Top Sells

Rank Stock Value
1
LRMR icon
Larimar Therapeutics
LRMR
+$4.64M
2
OCUL icon
Ocular Therapeutix
OCUL
+$3.33M
3
ACGN
Aceragen Inc
ACGN
+$2.48M
4
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$2.06M
5
PRQR icon
ProQR Therapeutics
PRQR
+$1.95M

Sector Composition

Rank Sector Weight
1 Healthcare 9.16%
2 Energy 0.42%
3 Industrials 0.14%
4 Consumer Staples 0.11%
5 Technology 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
THC icon
76
PUT
Tenet Healthcare
THC
$22.5B
$4.48K 0.14%
+884
New +$46.2K
SGMO
77
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$4.46K 0.14%
293,500
-126,623
-30% -$1.54M
QRHC icon
78
Quest Resource Holding
QRHC
$27.8M
$4.35K 0.14%
377,241
+86,768
+30% +$1.01M
RMTI icon
79
CALL
Rockwell Medical
RMTI
$26.8M
$4.16K 0.13%
+37
New +$38K
SHPG
80
PUT
DELISTED
Shire pic
SHPG
$3.89K 0.12%
183
– –
THMO
81
DELISTED
ThermoGenesis Holdings, Inc. Common Stock
THMO
$3.77K 0.12%
411
+16
+4% +$159K
NKTR icon
82
CALL
Nektar Therapeutics
NKTR
$2.34B
$3.69K 0.12%
+159
New +$34K
NBIX icon
83
PUT
Neurocrine Biosciences
NBIX
$18.3B
$3.61K 0.11%
1,614
+300
+23% +$5.68K
PBYI icon
84
Puma Biotechnology
PBYI
$399M
$3.57K 0.11%
+18,860
New +$4.18M
NBIX icon
85
CALL
Neurocrine Biosciences
NBIX
$18.3B
$3.56K 0.11%
1,593
-82
-5% -$1.55K
APEN
86
DELISTED
Apollo Endosurgery, Inc.
APEN
$3.52K 0.11%
16,209
-4,935
-23% -$1.1M
ABEO icon
87
Abeona Therapeutics
ABEO
$343M
$3.47K 0.11%
+39,624
New +$3.55M
LRMR icon
88
Larimar Therapeutics
LRMR
$387M
$3.43K 0.11%
9,272
-18,025
-66% -$4.64M
ACHN
89
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
$3.33K 0.11%
2,719
-11,496
-81% -$140K
RIBT
90
DELISTED
RiceBran Technologies
RIBT
$3.33K 0.11%
+79,920
New +$3.39M
RPRX
91
PUT
DELISTED
Repros Therapeutics Inc.
RPRX
$3.15K 0.1%
3,161
-299
-9% -$2.55K
INFI
92
CALL
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$3.15K 0.1%
1,865
+877
+89% +$12.8K
CELG
93
CALL
DELISTED
Celgene Corp
CELG
$3.13K 0.1%
280
-2,040
-88% -$215K
ACAD icon
94
PUT
Acadia Pharmaceuticals
ACAD
$4.44B
$3.09K 0.1%
+973
New +$27.6K
INFI
95
PUT
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$3.05K 0.1%
1,807
+456
+34% +$6.64K
EXAS
96
PUT
DELISTED
Exact Sciences
EXAS
$2.94K 0.09%
1,072
-82
-7% -$2K
KEYS icon
97
Keysight
KEYS
$51.8B
$2.84K 0.09%
+83,978
New +$2.74M
RMTI icon
98
Rockwell Medical
RMTI
$26.8M
$2.83K 0.09%
2,500
+576
+30% +$591K
RPRX
99
DELISTED
Repros Therapeutics Inc.
RPRX
$2.79K 0.09%
279,879
-15,742
-5% -$134K
PGEN icon
100
CALL
Precigen
PGEN
$1.96B
$2.75K 0.09%
1,046
– –
2 3
4
5 6

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2014 Portfolio in Review

As of Q4 2014, Sabby Management held 323 positions worth $3.17M, up 22% from $2.6M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management deployed $147M of net new capital in Q4 2014, opening 68 new positions and adding to 74 existing holdings. Its largest new stake was Pfizer: 1,322,658 shares worth $39.1K.

By sector, the portfolio is most concentrated in Healthcare at 9.2% of assets, up from 6.3% a quarter earlier, followed by Energy and Industrials.

On the sell side, the largest reduction was Larimar Therapeutics, an estimated $4.64M trimmed.

  • Sabby Management's largest Q4 2014 buy was Pfizer: 1,322,658 shares worth $39.1K.
  • Sabby Management added most to Achillion Pharmaceuticals in Q4 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q4 2014 reduction was Larimar Therapeutics, cutting an estimated $4.64M.
  • Sabby Management fully exited Aceragen Inc in Q4 2014, selling an estimated $2.48M.
  • Sabby Management's ten largest holdings make up 63% of its $3.17M portfolio in Q4 2014.
  • Sabby Management opened 68 new positions and closed 84 in Q4 2014.
  • Sabby Management's portfolio value rose 22% quarter-over-quarter to $3.17M.

Based on Sabby Management's 13F filing for Q4 2014, filed 17 Feb 2015.